Technology
Health
Pharmaceutical

Kindred Biosciences

$8.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (1.02%) Today
+$0.09 (1.02%) Today

Why Robinhood?

You can buy or sell KIN and other stocks, options, ETFs, and crypto commission-free!

About

Kindred Biosciences, Inc. Common Stock, also called Kindred Biosciences, is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. Read More The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Employees
146
Headquarters
Burlingame, California
Founded
2012
Market Cap
300.44M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
193.62K
High Today
$9.06
Low Today
$8.87
Open Price
$8.88
Volume
10.40K
52 Week High
$15.75
52 Week Low
$8.05

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Pets
2013 IPO
US
North America

News

Seeking AlphaMar 12

Kindred Bio: Call Me Inappetent

Kindred Bio (KIN) develops drugs for animals. The original idea was to study available generic drugs for humans that were already used for animals without proper trials or FDA approval, create a smart formulation which would be hard to copy (e.g., a transdermal patch) and a brand, and finally, sell these drugs through veterinarians. Since veterinarians not only treat pets but also sell the drugs they need (which our physicians are prohibited to do), veterinarians like new branded drugs a lot, as these allo...

84
The Motley FoolMar 6

Kindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript

Kindred Biosciences Inc (NASDAQ:KIN) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast for Kindred Biosciences. (Operator Instructions) Please note that the remarks today will include forward-looking statements and that actual results could differ materially from those projected or implied in our forward-looking s...

60
Seeking AlphaMar 6

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2018 Results - Earnings Call Transcript

Kindred Biosciences, Inc. (NASDAQ:KIN) Q4 2018 Earnings Conference Call March 6, 2019 4:30 PM ET Company Participants Richard Chin - Chief Executive Officer Denise Bevers - President & Chief Operating Officer Wendy Wee - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Ben Haynor - Alliance Global Partners Andrew DeSilva - B. Riley FBR Swayampakula Ramakanth - H.C. Wainwright Brooks O'Neil - Lake Street Capital Markets David Westenberg - Guggenheim Securitie...

0

Earnings

-$0.46
-$0.40
-$0.35
-$0.29
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.43 per share
Actual
-$0.46 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.